
    
      This is a non-interventional, prospective, observational post-marketing surveillance study of
      ixazomib citrate in participants with MM.

      The study will assess the safety and effectiveness of ixazomib citrate for its approved
      indications in a clinical practice setting under real-world conditions.

      The study will enroll approximately 600 participants. The data will be prospectively
      collected, at the centers from medical files and recorded into electronic case report forms
      (e-CRFs).

      All participants will be enrolled in a single observational group:

      â€¢ Participants With MM

      The study will be conducted in South Korea. The overall duration of the study will be
      approximately 6 years. Data will be collected over and up to a 6 months-surveillance period
      (per participant) once enrolled.
    
  